This role has been demonstrated by targeting of Bruton’s tyrosine kinase (BTK), a pivotal enzyme in the BCR signaling nexus [3], with small-molecule inhibitors, which results in prolonged disease-free survival in CLL. Here, BTK is linked to B-cell chronic lymphocytic leukemia.